This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


2jix

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:2jix.jpg|left|200px]]
+
{{Seed}}
 +
[[Image:2jix.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2jix| PDB=2jix | SCENE= }}
{{STRUCTURE_2jix| PDB=2jix | SCENE= }}
-
'''CRYSTAL STRUCTURE OF ABT-007 FAB FRAGMENT WITH THE SOLUBLE DOMAIN OF EPO RECEPTOR'''
+
===CRYSTAL STRUCTURE OF ABT-007 FAB FRAGMENT WITH THE SOLUBLE DOMAIN OF EPO RECEPTOR===
-
==Overview==
+
<!--
-
Recombinant human erythropoietin (rHu-EPO) is used to treat anemia by activating the erythropoietin receptor (EPOR) in erythroid progenitor cells, leading to proliferation and differentiation into mature red blood cells. To allow less frequent dosing, a hyperglycosylated version of EPO has been developed with a longer half-life. In principle, an agonistic antibody targeting EPOR would offer an even longer half-life, support robust monthly dosing, and, unlike EPO products, reduce the risk of pure red cell aplasia. The efficiency of signaling and corresponding potency of previously reported antibody mimics are generally suboptimal compared with EPO and not suitable for clinical use. Here we describe a potent, fully human, agonistic antibody (ABT007) targeting EPOR that supports potent, more sustained, and less pulsatile elevation of hematocrit in a human EPOR-expressing transgenic mouse model compared with standard doses of rHu-EPO while requiring less frequent dosing. Resolution of the crystal structure of the EPOR extracellular domain (ECD) complexed to the ABT007 Fab fragment, determined at 0.32 nm, identifies a binding site that is consistent with a novel mechanism of receptor activation based on a unique antibody-imposed conformational change. These results demonstrate that a symmetric molecule can serve as a potent activator of the EPOR.
+
The line below this paragraph, {{ABSTRACT_PUBMED_17620453}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 17620453 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_17620453}}
==About this Structure==
==About this Structure==
Line 47: Line 51:
[[Category: Transmembrane]]
[[Category: Transmembrane]]
[[Category: Ubl conjugation]]
[[Category: Ubl conjugation]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 08:59:43 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 08:09:40 2008''

Revision as of 05:09, 28 July 2008

Image:2jix.png

Template:STRUCTURE 2jix

CRYSTAL STRUCTURE OF ABT-007 FAB FRAGMENT WITH THE SOLUBLE DOMAIN OF EPO RECEPTOR

Template:ABSTRACT PUBMED 17620453

About this Structure

2JIX is a Protein complex structure of sequences from Escherichia coli. Full crystallographic information is available from OCA.

Reference

A potent erythropoietin-mimicking human antibody interacts through a novel binding site., Liu Z, Stoll VS, Devries PJ, Jakob CG, Xie N, Simmer RL, Lacy SE, Egan DA, Harlan JE, Lesniewski RR, Reilly EB, Blood. 2007 Oct 1;110(7):2408-13. Epub 2007 Jul 9. PMID:17620453

Page seeded by OCA on Mon Jul 28 08:09:40 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/2jix"
Personal tools